Compare Abbott Laboratories (ABT) vs ARK Autonomous Technology & Robotics ETF (ARKQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs ARK Autonomous Technology & Robotics ETF — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while ARK Autonomous Technology & Robotics ETF trades at $123.81. The key difference: Abbott Laboratories pays a 2.63% dividend while ARK Autonomous Technology & Robotics ETF pays none, and ARK Autonomous Technology & Robotics ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | ARKQ | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $143.82 |
52-Week Low | $82.57 | $88.47 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ARKQ trades at $130.11, up 1.7% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum, with assets under management reaching $2.7 billion as of April 2026 (Seeking Alpha, 2026-04-26). Recent news highlights sector growth in AI, robotics, and autonomous vehicles, though valuation metrics like P/E are not provided in the current data.
Outlook remains tied to AI and robotics adoption, with potential from themes like humanoid robots and autonomous driving. Risks include high valuations, sector volatility, and reliance on tech spending. Analyst sentiment is mixed, with some upgrades citing growth potential but technical indicators suggesting near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →
